🟠SS-31 | 10mg 🏆 Amber Edition

SS-31, also known as Elamipretide, is a synthetic tetrapeptide that has been extensively studied for its role in mitochondrial protection and its potential therapeutic effects in treating various diseases associated with mitochondrial dysfunction. SS-31 works by selectively targeting cardiolipin, a phospholipid that plays a critical role in maintaining mitochondrial structure and function.

SS-31 has a high affinity for cardiolipin, a lipid found exclusively in the inner mitochondrial membrane. Cardiolipin is crucial for stabilizing proteins involved in mitochondrial respiration and ATP production. Under conditions of stress, cardiolipin becomes oxidized, leading to mitochondrial dysfunction and cell death. SS-31 binds to cardiolipin and prevents its oxidation, thereby preserving mitochondrial function and reducing the production of reactive oxygen species (ROS).

By binding to cardiolipin, SS-31 stabilizes the mitochondrial membrane and enhances the efficiency of the electron transport chain (ETC), particularly at complex I and complex III. This stabilization reduces electron leakage, preventing the formation of superoxide, a precursor of ROS. The preservation of the ETC function helps maintain optimal ATP production, which is critical for energy-demanding tissues like the heart, brain, and skeletal muscles.

One of SS-31’s key effects is its ability to reduce mitochondrial ROS levels. Excessive ROS production leads to oxidative stress, damaging cellular components such as lipids, proteins, and DNA. By preventing ROS formation at the mitochondrial level, SS-31 mitigates oxidative damage and inflammation, contributing to overall cellular health.

SS-31 has been shown to improve mitochondrial bioenergetics, particularly in cells experiencing metabolic stress. By enhancing the function of the electron transport chain and reducing oxidative damage, SS-31 promotes efficient ATP synthesis. This effect is particularly beneficial in conditions like heart failure, neurodegenerative diseases, and age-related mitochondrial decline, where mitochondrial dysfunction is a hallmark.

SS-31 is being investigated in various clinical trials for its potential to treat a range of mitochondrial disorders and age-related diseases. Preclinical and early clinical studies have demonstrated its efficacy in improving mitochondrial function in models of heart failure, ischemia-reperfusion injury, neurodegenerative diseases, and muscle atrophy.

It represents a novel therapeutic peptide that targets mitochondrial dysfunction at its source. Its unique ability to stabilize cardiolipin and improve mitochondrial bioenergetics makes it a promising candidate for treating diseases with underlying mitochondrial damage. Ongoing clinical trials will provide further insights into its potential applications in cardiovascular, neurodegenerative, and muscular diseases.